Digital & Personalised Healthcare (PHC)
Ban katantaFor more than 20 years, Roche and Genentech have helped lay the scientific groundwork for personalised healthcare with treatments that target the underlying biology of cancer and other diseases.
Now we are working on taking personalised healthcare toward a future in which treatments are targeted to an individual’s needs and unique genetic profile. Our personalised healthcare partnering strategy is built around identifying strategic partners with whom we can pursue this vision. With Flatiron and Foundation Medicine as part of the Roche Group we are shaping new ways of realising the promise of personalised healthcare.
Partnering opportunities we are looking for:
- Robust data sets
- Advanced Analytics (artificial intelligence including machine learning and deep-learning models)
- Digital and mobile technologies
Foundation Medicine (FMI) – acquisition to further develop FMI's comprehensive genomic profiling platform and support Roche’s PHC strategy
Flatiron – acquisition to advance use of real-world evidence in regulatory decision-making and at point of care
- global partnership to develop a digital therapeutic technology for individuals living with autism